1st Annual Regen Med Investor Day Clinical Outlooks in Cardiovascular Disease

Marc Hedrick, MD Cytori Therapeutics (NASDAQ:CYTX)

President

April 17, 2013

Safe Harbor Statement

This presentation contains certain ‘forward-looking statements’ about Cytori Therapeutics, Inc. All

statements, other than statements of historical fact, that address activities, events or developments that we

intend, expect, project, believe or anticipate will or may occur in the future are forward-looking statements.

Such statements are based upon certain assumptions and assessments made by our management in light of

their experience and their perception of historical trends, current conditions, expected future developments

and other factors they believe to be appropriate.

The forward-looking statements included in this presentation involve known and unknown risks that relate to

Cytori’s future events or future financial performance and the actual results could differ materially from those

discussed in this presentation. Risks and uncertainties that may cause Cytori's actual results to differ

materially from those discussed in the presentation can be found in the "Risk Factors" section of Cytori’s

Form 10-K, Forms 10-Q and other filings with the United States Securities and Exchange Commission. We

would advise reading our most recent annual report on Form 10-K and quarterly report on Form 10-Q filed

with the United States Securities and Exchange Commission for a more detailed description of these risks.

The forward-looking statements contained in this presentation represent Cytori’s estimates and assumptions

only as of the date of this presentation and Cytori undertakes no duty or obligation to update or revise

publicly any forward-looking statements contained in this presentation as a result of new information, future

events or changes in Cytori’s expectations.

Cytori Cell Therapy: Unique Attributes

Proprietary formulation of ADRCs

•Autologous

•Mixed cell population

•Various mechanisms

•Patented process

•Virtually ‘off the shelf’

Cytori Cell Therapy: Heterogeneity

Mechanisms of Action

• Paracrine (local GF

delivery)

• Differentiation

• Inflammatory modulation

• Angiogenesis

• Wound healing

Tissue Macrophages

23%

White Blood Cells

22% Stem Cells

2%

CD34+/CD31-

37%

Endothelial Cells

7%

Vascular

Smooth

Muscle Cells

9%

Cytori Cell Therapy: Cardiovascular Trials

EU Pilot US Pilot Pivotal

Acute MI

Complete In Progress

APOLLO

N = 14, Europe

ADVANCE

N = 216, Europe

Chronic

Myocardial

Ischemia

Complete In Progress Preliminary

PRECISE

N = 27, Europe

ATHENA

N = 45, USA

ATHENA II

N=TBD,

International

Summary from European Pilot Trials

• AMI- safe and trend toward reduction in infarct size, favorable remodeling

• HF & CMI- safe & statistically significant stabilization in Max VO2

Cytori Cell Therapy: Economics

System:

• Low six figure ASP (current generation)

• Next-generation system COGS~ $10,000, flexible model

Procedures /

Year

Est. Consumable

ASP Est. Revenue

Est. Consumable

Gross Profit

100,000 $10,000 $1 Billion $800 + Million

Per-procedure consumable:

• $8,000-$12,000 for vascular indications

• >80% GM